Evolus (EOLS) Change in Accured Expenses (2017 - 2026)
Evolus (EOLS) posted Change in Accured Expenses of -$3.7 million for Q1 2026, down 194.69% on a QoQ basis from $4.0 million in Q4 2025, and up 73.58% year-over-year from -$2.2 million in Q1 2025.
Evolus (EOLS) Change in Accured Expenses (2017 - 2026) Analysis & Trends
Evolus' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$3.7 million for Q1 2026.
- Quarterly Change in Accured Expenses rose 73.58% year-over-year to -$3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (up 141.9% YoY) and the FY2025 annual result came in at -$6.4 million, down 191.2% from the prior year.
- Change in Accured Expenses was -$3.7 million for Q1 2026 at Evolus, down from $4.0 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $7.9 million in Q2 2024 and bottomed at -$14.2 million in Q1 2025.
- A 5-year average of $40588.2 and a median of $2.1 million in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 355.53% — and 2024, when it surged 278.36%.
- Evolus' Change in Accured Expenses stood at -$5.1 million in 2022, then surged by 239.52% to $7.1 million in 2023, then dropped by 17.73% to $5.8 million in 2024, then slumped by 32.31% to $4.0 million in 2025, then sank by 194.69% to -$3.7 million in 2026.
- Business Quant data shows EOLS's Change in Accured Expenses at -$3.7 million in Q1 2026, $4.0 million in Q4 2025, and $2.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.24 Bn | 87.37 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.17 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.28 Bn | 21.13 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 20.54 Bn | 20.54 Bn | - | - |
| 7 | Viatris | 20.31 Bn | 18.50 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.55 Bn | 12.12 Bn | 785.00 Mn | - |
| 10 | Evolus | 407.09 Mn | 357.30 Mn | 48.90 Mn | -3.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.74 Mn |
| Mar 31, 2026 | -3.74 Mn |
| Dec 31, 2025 | 3.95 Mn |
| Dec 31, 2025 | 3.95 Mn |
| Sep 30, 2025 | 2.52 Mn |
| Sep 30, 2025 | 2.52 Mn |
| Jun 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 1.34 Mn |
| Mar 31, 2025 | -14.17 Mn |
| Mar 31, 2025 | -14.17 Mn |
| Dec 31, 2024 | 5.84 Mn |
| Dec 31, 2024 | 5.84 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Jun 30, 2024 | 7.85 Mn |
| Jun 30, 2024 | 7.85 Mn |
| Mar 31, 2024 | -8.87 Mn |
| Mar 31, 2024 | -8.87 Mn |
| Dec 31, 2023 | 7.10 Mn |
| Dec 31, 2023 | 7.10 Mn |